GlassScriptPhysician profile
Sean Jochims
NPI 1861401473
$2,170.01
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $684 · 2021: $349.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $360.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $211.73 | 2019-2021 | |
| Acorda Therapeutics, INC | $165.88 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $149.98 | 2019-2020 | |
| Eisai INC. | $125.00 | 2019 | |
| Lundbeck LLC | $121.16 | 2019-2021 | |
| Abbvie INC. | $101.80 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $84.10 | 2019-2021 | |
| Livanova USA, INC. | $82.95 | 2019 | |
| Neurocrine Biosciences, INC. | $76.17 | 2020-2021 | |
| Biogen, INC. | $64.89 | 2019-2020 | |
| Amgen INC. | $62.33 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $61.54 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $57.28 | 2019-2020 | |
| Harmony Biosciences LLC | $55.68 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.40 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $32.05 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $31.33 | 2021 | |
| Ucb, INC. | $30.96 | 2019-2020 | |
| Greenwich Biosciences, INC. | $30.66 | 2019 | |
| Mdd US Operations, LLC | $30.46 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $27.46 | 2019-2020 | |
| Allergan, INC. | $26.79 | 2019 | |
| Upsher-Smith Laboratories LLC | $24.23 | 2021 | |
| Acadia Pharmaceuticals INC | $20.36 | 2019 | |
| Abbott Laboratories | $20.12 | 2021 | |
| Celgene Corporation | $17.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.50 | 2020 | |
| Kyowa Kirin, INC. | $13.71 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.47 | 2020 | |
| Pfizer INC. | $10.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Jochims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.